123 results
424B5
IKT
Inhibikase Therapeutics Inc
22 May 24
Prospectus supplement for primary offering
8:55am
regarding our ability to continue as a going concern and our independent registered public accounting firm has included an explanatory paragraph relating … conditions and events that raise doubt about our ability to continue as a going concern and our independent registered public accounting firm has
8-K
EX-4.3
IKT
Inhibikase Therapeutics Inc
20 May 24
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant
8:55am
by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable … of Common Stock as determined by an independent appraiser selected in good faith by the holders of a majority in interest.
Section 2. Exercise
8-K
EX-4.2
IKT
Inhibikase Therapeutics Inc
20 May 24
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant
8:55am
by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable … of a share of Common Stock as determined by an independent appraiser selected in good faith by the holders of a majority in interest.
Section 2. Exercise
8-K
EX-4.4
IKT
Inhibikase Therapeutics Inc
20 May 24
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant
8:55am
by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable … of a share of Common Stock as determined by an independent appraiser selected in good faith by the holders of a majority in interest.
Section 2. Exercise
8-K
EX-10.1
IKT
Inhibikase Therapeutics Inc
20 May 24
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant
8:55am
the Securities Act);
(xi) a comfort letter from CohnReznick LLP (the independent registered public accounting firm of the Company), addressed to the Placement … or, to the knowledge of the Company, is imminent with respect to any of the employees, independent contractors or consultants of the Company, which
8-K
EX-10.2
mjd342q3
20 May 24
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant
8:55am
8-K
EX-4.1
kchapywim y1nvf
20 May 24
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant
8:55am
8-K
EX-4.5
4pp crg9ska4
20 May 24
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant
8:55am